No Data
No Data
U.S. stock abnormality | Northeast securities maintains a "buy" rating, and hutchmed (china) (HCM.US) rose more than 8%.
As of press time, the stock has risen over 8% to $19.245.
HK stocks fluctuation: Hutchmed (China) (00013) rises by more than 9% again, the company recently shared the latest pipeline progress, institutions stated that there are multiple catalysts in the second half of the year.
Hutchmed (China) (00013) rose more than 9%, as of press time, it rose 7.03% to HKD 29.7, with a turnover of HKD 0.114 billion.
Bocom Intl maintains a buy rating for Hutchmed (China) (00013) with a target price of HK$40.
According to the report released by Bocom International on the Zhongtong Finance and Economics App, they maintain buy rating for Hutchmed (China) (00013) with a target price of HKD 40. The report stated that the catalysts for the second half of 2024 include global sales of Fruquintinib and domestic approval progress based on Frutiga research for 2L gastric cancer as well as global declaration based on SAVANNAH research for Savolitinib. The domestic approval for Surufatinib was also mentioned. The bank pointed out that the effectiveness of the combination therapy of Sulfatinib and PD-1 for pancreatic cancer treatment is encouraging. One IIT data announced at ASCO GI conference showed that the combination of Sulfatinib and AS therapy is
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $29
BofA Securities analyst Alec Stranahan maintains $Hutchmed (China)(HCM.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 46.2%
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Soochow Securities: "Implementation Plan for Supporting the Development of Innovative Drugs Across the Entire Chain" Approved, and the innovative drugs sector is expected to strengthen.
Soochow Securities released research reports stating that the specific provisions of the "Implementation Plan for Full-chain Support of Innovative Drug Development" are expected to be implemented soon. In addition, the innovative drug sector is currently at a historically relatively low level. In the second half of the year, there will be multiple catalysts such as the ESMO conference, WCLC conference, medical insurance negotiations, and expectations for the innovative drug sector going global, which may lead to a strong performance in the innovative drug sector.
DailyHunt : Do you think is ready?
Momentum TraderOP DailyHunt: Already Bo from pivot. Don’t chase high!